The Global Clostridium Butyricum Market was valued at USD 1.2 Billion in 2024 and is projected to reach USD 2.1 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period (2024–2032). This robust growth is being driven by increasing consumer awareness of gut health, the global shift away from antibiotic growth promoters in animal feed, and expanding pharmaceutical applications for gastrointestinal therapeutics.

As the healthcare and nutrition industries pivot towards microbiome-based solutions, the spotlight is on the key microbial innovators who are driving research, production, and commercialization. In this blog, we profile the Top 10 Companies in the Clostridium Butyricum Industry—a dynamic mix of pharmaceutical pioneers, specialized probiotic firms, and biotech leaders shaping the future of microbial health.

---

🔟 10. Daflorn Ltd.

Headquarters: Sofia, Bulgaria
Key Offering: Clostridium butyricum API (Active Pharmaceutical Ingredient), Probiotic Raw Materials

Daflorn Ltd. is a prominent European supplier of high-purity active pharmaceutical ingredients and probiotic raw materials, with a focus on Clostridium butyricum strains. The company serves pharmaceutical manufacturers and nutraceutical formulators across the continent, emphasizing quality control and regulatory compliance for the European market.

Innovation & Market Focus:

• Specialized in GMP-grade microbial ingredients

• Strong distribution network within Eastern and Central Europe

• Focus on supplying clinical research and pharmaceutical production

Download FREE Sample Report:
Global Clostridium Butyricum Market – View in Detailed Research Report

---

9️⃣ 9. Advanced Enzyme Technologies Ltd.

Headquarters: Thane, India
Key Offering: Clostridium butyricum-based formulations, Synbiotic blends

Advanced Enzyme Technologies, a leader in enzyme manufacturing, has expanded into the probiotic space with specialized Clostridium butyricum products. Leveraging its fermentation expertise, the company develops synbiotic formulations that combine probiotics with prebiotics for enhanced efficacy in human nutrition and animal health segments.

Innovation & Market Focus:

• Integration of enzyme and probiotic technologies

• Cost-effective production for price-sensitive markets

• Growing footprint in the Asia-Pacific animal feed additive sector

---

8️⃣ 8. MITUSHI BIO PHARMA

Headquarters: Gujarat, India
Key Offering: Pharmaceutical-grade Clostridium butyricum, Probiotic sachets and capsules

MITUSHI BIO PHARMA is an India-based company specializing in the research and production of spore-forming probiotics. It has established itself as a key domestic supplier of Clostridium butyricum for both over-the-counter digestive health products and prescription-based formulations targeting specific gastrointestinal disorders.

Innovation & Market Focus:

• Focus on affordable therapeutics for emerging markets

• Development of combination products with other beneficial strains

• Active in clinical collaborations with Indian medical institutions

---

7️⃣ 7. Winclove Probiotics

Headquarters: Amsterdam, Netherlands
Key Offering: Customized probiotic blends, Ecologic® formulations featuring C. butyricum

Winclove Probiotics is a Dutch pioneer in developing evidence-based, multi-strain probiotic formulations. The company incorporates Clostridium butyricum into its proprietary Ecologic® blends, which are backed by scientific research and targeted at specific health conditions, from intestinal barrier support to immune modulation.

Innovation & Market Focus:

• Strong emphasis on clinical validation and human studies

• B2B focus, supplying bespoke blends to global brands

• Leading expertise in synbiotic (pro + prebiotic) innovation

---

6️⃣ 6. Sabinsa Corporation

Headquarters: East Windsor, New Jersey, USA
Key Offering: SabiBiotic® (probiotic ingredients), Clostridium butyricum as a dietary supplement ingredient

Sabinsa Corporation, a globally recognized name in phytochemicals and cosmeceuticals, has a significant presence in the probiotic market. The company offers Clostridium butyricum as part of its SabiBiotic® line, focusing on the ingredient’s application in dietary supplements for digestive wellness and metabolic health.

Innovation & Market Focus:

• Leverages extensive global distribution network

• Commitment to scientific research and patent-protected ingredients

• Exploration of C. butyricum in new health areas like metabolic syndrome

Download FREE Sample Report:
Global Clostridium Butyricum Market – View in Detailed Research Report

---

5️⃣ 5. Lallemand Inc.

Headquarters: Montreal, Canada
Key Offering: Clostridium butyricum for animal nutrition (Bactocell®), Human probiotic strains

Lallemand Inc. is a global leader in yeast and microbial solutions, with a major division dedicated to animal nutrition and health. Its application of Clostridium butyricum is particularly strong in the aquaculture and livestock sectors, where it is used to improve gut health, feed efficiency, and disease resistance as a natural alternative to antibiotics.

Innovation & Market Focus:

• World leader in microbials for animal health

• Extensive R&D in strain-specific modes of action

• Strong focus on sustainability and reducing antibiotic use in farming

---

4️⃣ 4. Hangzhou Vega Co., Ltd.

Headquarters: Hangzhou, China
Key Offering: Clostridium butyricum bulk powder, Animal feed probiotics, Pharmaceutical intermediates

Hangzhou Vega is a major Chinese manufacturer and supplier of microbial products, including high-volume Clostridium butyricum. The company plays a critical role in the Asia-Pacific supply chain, catering primarily to the massive animal feed industry in China and Southeast Asia, where regulatory approval for probiotic use is expanding rapidly.

Innovation & Market Focus:

• Large-scale, cost-competitive fermentation production

• Dominant supplier to the Asian animal nutrition market

• Increasing investment in pharmaceutical-grade production facilities

---

3️⃣ 3. AOR Canada

Headquarters: Calgary, Canada
Key Offering: Advanced probiotic formulations, C. butyricum in shelf-stable delivery systems

AOR (Advanced Orthomolecular Research) is a respected Canadian nutraceutical company known for its scientifically rigorous formulations. It has integrated Clostridium butyricum into its advanced probiotic lines, utilizing sophisticated encapsulation technologies to ensure bacterial survival through gastric transit and enhance colonization in the gut.

Innovation & Market Focus:

• Pioneer in advanced delivery systems for probiotic viability

• Strong direct-to-consumer and practitioner channels in North America

• Focus on condition-specific formulations with clinical rationale

---

2️⃣ 2. Biofermin Pharmaceutical Co., Ltd. (affiliated with Miyarisan)

Headquarters: Kobe, Japan
Key Offering: Miyarisan® (Clostridium butyricum MIYAIRI 588 strain) tablets and powder

While Miyarisan Pharmaceutical is the innovator, Biofermin Pharmaceutical is a key commercial entity in the Japanese market for the flagship MIYAIRI 588 strain. This strain is one of the most clinically documented Clostridium butyricum probiotics in the world, approved in Japan for decades for treating antibiotic-associated diarrhea and other intestinal ailments.

Innovation & Market Focus:

• Exclusive focus on the proprietary, highly-researched MIYAIRI 588 strain

• Deep market penetration in Japan’s pharmaceutical and OTC sectors

• Gold standard for safety and efficacy data on C. butyricum

Get Full Report Here:
Global Clostridium Butyricum Market – View in Detailed Research Report

---

1️⃣ 1. Miyarisan Pharmaceutical Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: Patented Clostridium butyricum MIYAIRI 588 strain, Pharmaceutical-grade probiotics

Miyarisan Pharmaceutical is the undisputed global pioneer and leader in the Clostridium butyricum market. The company discovered and patented the MIYAIRI 588 strain, which has been the subject of extensive clinical research since the 1960s. Its products are prescribed by physicians and are a cornerstone of probiotic therapy in Japan, setting the benchmark for quality and scientific validation worldwide.

Innovation & Market Focus:

• Global intellectual property leader for the MIYAIRI 588 strain

• Unmatched depth of clinical evidence supporting specific health claims

• Focus on pharmaceutical applications and strategic global licensing

---

🌍 Outlook: The Future of the Clostridium Butyricum Market Is Personalized and Precision-Based

The Clostridium butyricum market is undergoing a significant evolution. While traditional animal feed and pharmaceutical applications continue to drive volume, the industry is investing heavily in next-generation applications, strain-specific genomics, and personalized microbiome solutions.

📈 Key Trends Shaping the Market:

• Expansion beyond gut health into metabolic, neurological, and immune research (the gut-brain and gut-liver axes)

• Rising demand in aquaculture as a sustainable alternative to antibiotics

• Increasing use in functional foods and beverages, driven by microencapsulation tech for stability

• Growth of direct-to-consumer microbiome testing creating demand for personalized probiotic regimens featuring targeted strains like C. butyricum

Get Full Report Here:
Global Clostridium Butyricum Market – View in Detailed Research Report

The companies listed above are not only supplying a critical microbial ingredient—they’re pioneering the science-led transition towards a more preventive and microbiome-centric approach to human and animal health.